

- 2. Data reduction based on a molecular signature unmasks information on cell tumorigenic potential.
- 3. Specific amino acid and lipid metabolic pathways distinguish GBM cells with high tumorigenic potential.
- 4. ELOVL2, a key enzyme for very long chain-PUFA synthesis, is required for GBM cell tumorigenicity.
- factor signature driving glioblastoma cell aggressiveness. Acta Neuropathologica 2018 ВІОГОВІ Saurty-Seerunghen et al. Capture at the single cell level of metabolic modules distinguishing aggressive and indolent glioblastoma cells. Acta Neuropathologica Communications 2019

· Bogeas et al. Changes in chromatin state reveal ARNT2 at a node of a tumorigenic transcription

2019

*** île**de**France**

LALIQUI